Italy ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

Italy Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The Italy Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $709 Mn in 2022 and is projected to reach $1,219 Mn in 2030, exhibiting a CAGR of 7% during the forecast period. The Italian government has allocated $133.55 Bn to the national health system due to staff gaps and lengthy treatment wait lists. The most recent Budget Law that has been approved covers the entire planned spending for the Italian state over the three-year term 2022-2024 and is quite comprehensive. The national NHS funding is expected to rise overall by $2.14 Bn over the next three years. Accordingly, the budget will total $132.48 Bn in 2022 and $136.75 Bn in 2024.

ADHD is acknowledged as a challenging diagnosis to make correctly due to the high prevalence of comorbid conditions as well as the low specificity of the core symptoms. There are a virtually endless number of disorders or conditions that can cause a kid to appear restless or distractible. A thorough assessment of the child's development, educational requirements, what is expected of the child in a given situation and at a given moment, as well as symptomatology, impairment, and risk, is thus necessary to make a proper diagnosis. About 1.3% of primary and middle school students in Italy are thought to have severe ADHD.

ADHD therapy should be based on a multimodal approach combining psychological counseling with pharmacological treatment options and should take into account the subject's characteristics, including age, symptom severity, co-morbid disorders, cognitive level, and social and family context. The medication of preference for treating attention deficit hyperactivity disorder is methylphenidate. It is only available in one formulation in Italy, which is less than ideal for assuring an effective course of treatment. Despite the small number of patients receiving treatment, they frequently favor using prolonged-release formulations sold abroad because it is simpler for them to adhere to dose instructions. An integrated pharmacological and psychotherapeutic strategy is effective in treating adult ADHD in Italy. Due to its treatment responsiveness, disability is decreased and the common comorbidity can be handled. Complex regimens significantly lower patient adherence to therapy. Treatment for a syndrome like ADHD, where cognitive dysfunction is prevalent, must be straightforward and organized. the incorporation of everyday routines and built-in reminders (mobile phone apps with audible alerts are again useful).

Market Dynamics

Market Growth Drivers

It is likely that as ADHD becomes more common in Italy, there will be a rise in the number of cases that are identified and a corresponding rise in the demand for ADHD medications. More people are likely to seek diagnosis and treatment as the general public and medical professionals' knowledge of ADHD rises. This might result in a rise in the demand for Italy's ADHD therapeutics market. Since they have fewer adverse effects than stimulants, non-stimulant medications for the treatment of ADHD have seen an increase in popularity in recent years. The market for non-stimulant ADHD medications could expand as a result of this trend, which is likely to persist.

Market Restraints

While the general public and some healthcare professionals are becoming more conscious of ADHD, there is still a lack of understanding of the condition. This might result in a misdiagnosis and inadequate care of ADHD, which would restrict Italy's ADHD therapeutics market expansion.  The cost of some ADHD medications may prevent some patients from receiving therapy. This might result in a smaller market and constrain the market's expansion for ADHD. Stimulant drugs, which are frequently prescribed to treat ADHD, can have adverse effects like suppressed hunger and disturbed sleep. This might cause patients to stop taking their medications or look for alternative therapies, which would slow the market expansion for ADHD therapeutics in Italy.

Competitive Landscape

Key Players

• Medexport (ITA)
• Farmigea (ITA)
• Abiogen Pharma (ITA)
• Farmaka (ITA)
• Medac Pharma (ITA)
• Alcobra
• Amarantus Bioscience
• Curemark,
• Eli Lilly
• Intellipharmaceutics International
• Janssen Global Services
• Mallinckrodt
• Mylan

Healthcare Policies and Regulatory Landscape

The state organization in charge of drug regulation in Italy since 2004 is the Italian Medicines Agency (Agenzia Italiana del Farmaco, or AIFA). It is a public organization that operates independently, openly, and in accordance with cost-effectiveness standards, under the supervision of the Ministry of Health and the Ministry of Economy. The National Institutes of Health, research organizations, patient associations, associations for professionals in the medical field, scientific associations of the pharmaceutical industry, and distributors are all partners in this collaboration. The objective is to encourage healthy living through drugs, managing the value and expense of medicines by establishing just pharmaceutical policies and ensuring their uniform application across the country. Regarding product marketing authorization, the Pharma Code of Italy states that the approval process for novel drug applications is the same as that generally anticipated for all medications. Nevertheless, there are programs to support the development of new medicines as well as simplified procedures for the authorization of generic medications.